Buchumschlag

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Luber, Birgit (VerfasserIn) , Deplazes, Joëlle (VerfasserIn) , Keller, Gisela (VerfasserIn) , Walch, Axel (VerfasserIn) , Rauser, Sandra (VerfasserIn) , Eichmann, Martin (VerfasserIn) , Langer, Rupert (VerfasserIn) , Höfler, Heinz (VerfasserIn) , Hegewisch-Becker, Susanna (VerfasserIn) , Folprecht, Gunnar (VerfasserIn) , Wöll, Ewald (VerfasserIn) , Decker, Thomas (VerfasserIn) , Endlicher, Esther (VerfasserIn) , Lorenzen, Sylvie (VerfasserIn) , Fend, Falko (VerfasserIn) , Peschel, Christian (VerfasserIn) , Lordick, Florian (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2011
In: BMC cancer
Year: 2011, Jahrgang: 11, Pages: 1-12
ISSN:1471-2407
DOI:10.1186/1471-2407-11-509
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-509
Verlag, lizenzpflichtig, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-509
Volltext
Verfasserangaben:Birgit Luber, Joëlle Deplazes, Gisela Keller, Axel Walch, Sandra Rauser, Martin Eichmann, Rupert Langer, Heinz Höfler, Susanna Hegewisch-Becker, Gunnar Folprecht, Ewald Wöll, Thomas Decker, Esther Endlicher, Sylvie Lorenzen, Falko Fend, Christian Peschel and Florian Lordick
Beschreibung
Zusammenfassung:The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising objective tumour response rate of 65% and a low mutation frequency of KRAS (3%). The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX.
Beschreibung:Gesehen am 10.11.2022
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-509

Ähnliche Einträge